Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence
How Is the Palmoplantar Pustulosis Market Size Expected to Evolve From 2025 to 2029?
The palmoplantar pustulosis market size has grown strongly in recent years. It will grow from $1.93 billion in 2024 to $2.09 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increasing prevalence of autoimmune disorders, growing awareness about rare skin diseases, rising healthcare expenditure, rising healthcare expenditure, and growing telemedicine adoption for dermatology.
The palmoplantar pustulosis market size is expected to see strong growth in the next few years. It will grow to " $2.82 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to rising adoption of biologic therapies, increasing investments in dermatology research, growing pipeline of novel treatments, rising demand for personalized medicine, increasing prevalence of chronic skin conditions. Major trends in the forecast period include advancements in dermatology research, shift towards biologics and immunomodulators, integration of artificial intelligence in dermatological diagnosis, development of advanced topical formulations, and integration of machine learning in dermatological research.
Get your free report sample today:
What Are the Leading Drivers Behind the Growth of the Palmoplantar Pustulosis Market?
The increasing incidence of skin disorders is expected to propel the growth of the palmoplantar pustulosis market going forward. Skin disorders refer to conditions that affect the skin's structure, function, or appearance. The increasing incidence of skin disorders is due to environmental changes, lifestyle habits, and genetic predisposition. Environmental factors such as air pollution, extreme weather conditions, and exposure to harmful chemicals can irritate the skin and lead to conditions like eczema or acne. Palmoplantar pustulosis is a chronic skin disorder that can significantly affect the skin on the palms of the hands and soles of the feet, leading to pustules, redness, and scaling, which can be managed through various treatments to improve skin health and alleviate discomfort. For instance, in 2022, according to the International Eczema Council, a US-based organization, in 2022, approximately 223 million people were affected by atopic dermatitis, with around 43 million being between the ages of 1 and 4. Therefore, the increasing incidence of skin disorders drives growth in the palmoplantar pustulosis market.
What Are the Emerging Segments Driving Growth in the Palmoplantar Pustulosis Market?
The palmoplantar pustulosismarket covered in this report is segmented –
1) By Treatment Type: Topical Treatments; Systemic Treatments; Biologics; Phototherapy
2) By Application: Hospitals; Dermatology Clinics; Homecare Settings
3) By Distribution Channel: Online Pharmacies; Retail Pharmacies; Hospitals
Subsegments:
1) By Topical Treatments: Corticosteroids; Vitamin D Analogues; Calcineurin Inhibitors; Keratolytics
2) By Systemic Treatments: Retinoids; Immunosuppressants; Phosphodiesterase-4 (PDE4) Inhibitors; Corticosteroids
3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin-17 (IL-17) Inhibitors; Interleukin-23 (IL-23) Inhibitors; Interleukin-12/23 (IL-12/23) Inhibitors
4) By Phototherapy: Narrowband UVB Therapy (NB-UVB); Psoralen plus Ultraviolet A (PUVA) Therapy; Excimer Laser Therapy; Targeted Phototherapy
What New Market Trends Are Emerging in the Palmoplantar Pustulosis Market?
Major companies operating in the palmoplantar pustulosis market are focusing on developing novel treatments, such as monoclonal antibodies targeting inflammatory pathways, to improve patient outcomes. A monoclonal antibody (mAb) is an identical antibody produced by a single clone of B cells, targeting a specific antigen for therapeutic or diagnostic use. For instance, in August 2023, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, received a partial change approval of LUMICEF for palmoplantar pustulosis in Japan. LUMICEF is a targeted therapy that blocks IL-17, offering rapid and sustained relief for inflammatory conditions such as psoriasis and palmoplantar pustulosis. Its purpose is to reduce inflammation and improve the quality of life for patients with these chronic diseases.
Who Are the Principal Market Leaders in the Palmoplantar Pustulosis Market?
Major companies operating in the palmoplantar pustulosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis International AG, GlaxoSmithKline PLC (GSK), Amgen Inc., C.H. Boehringer Sohn AG & Co. KG, Bausch Health Companies Inc., Chugai Pharmaceutical Co. Ltd., Janssen Pharmaceuticals Inc., Kyowa Kirin Co. Ltd., Swedish Orphan Biovitrum AB (Sobi), Almirall S.A., MorphoSys AG, MoonLake Immunotherapeutics AG, Aristea Therapeutics Inc., AnaptysBio Inc., Taiho Pharmaceutical Co. Ltd., Kamari Pharma Ltd.
Get the detailed palmoplantar pustulosis market report today
Which Regions Are Expected to Record the Strongest CAGR in the Palmoplantar Pustulosis Market?
North America was the largest region in the palmoplantar pustulosis market in 2024. The regions covered in the palmoplantar pustulosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment